Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes2012 · 399 citations
2. 2Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes2011 · 8 citations
3. 3Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy2008 · 3,836 citations
4. 4Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal1998 · 96 citations
5. 5Dose-Response Effects of Insulin Glargine in Type 2 Diabetes2010 · 44 citations